UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Gamma-delta (γδ) T cells: friend or foe in cancer development?

Journal of translational medicine, 2018-01, Vol.16 (1), p.3-13, Article 3

2018

Volltextzugriff (PDF)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors

Biomarker research, 2020-08, Vol.8 (1), p.34-34, Article 34

2020

Volltextzugriff (PDF)

Advances and applications of RNA vaccines in tumor treatment

Molecular cancer, 2024-10, Vol.23 (1), p.226-12, Article 226

2024

Volltextzugriff (PDF)

Regulation of fatty acid synthase on tumor and progress in the development of related therapies

Chinese medical journal, 2024-08, Vol.137 (16), p.1894-1902

2024

Volltextzugriff (PDF)

Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing

Frontiers in immunology, 2022-06, Vol.13, p.890166-890166

2022

Volltextzugriff (PDF)

The Lipid Metabolic Landscape of Cancers and New Therapeutic Perspectives

Frontiers in oncology, 2020-12, Vol.10, p.605154-605154

2020

Volltextzugriff (PDF)

Mechanisms of Cancer Resistance to Immunotherapy

Frontiers in oncology, 2020-08, Vol.10, p.1290-1290

2020

Volltextzugriff (PDF)

GCG inhibits SARS-CoV-2 replication by disrupting the liquid phase condensation of its nucleocapsid protein

Nature communications, 2021-04, Vol.12 (1), p.2114-2114, Article 2114

2021

Volltextzugriff (PDF)

Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy

Frontiers in immunology, 2022-05, Vol.13, p.886931-886931

2022

Volltextzugriff (PDF)

Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy

Journal of experimental & clinical cancer research, 2019-09, Vol.38 (1), p.403-403, Article 403

2019

Volltextzugriff (PDF)

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

Journal of thoracic oncology, 2021-09, Vol.16 (9), p.1501-1511

2021

Volltextzugriff (PDF)

Microplastics: an often-overlooked issue in the transition from chronic inflammation to cancer

Journal of translational medicine, 2024-10, Vol.22 (1), p.959-11, Article 959

2024

Volltextzugriff (PDF)

FLI-1-driven regulation of endothelial cells in human diseases

Journal of translational medicine, 2024-08, Vol.22 (1), p.740-14, Article 740

2024

Volltextzugriff (PDF)

Epidermal growth factor receptor compound and concomitant mutations: advances in precision treatment strategies

Chinese medical journal, 2023-12, Vol.136 (23), p.2776-2786

2023

Volltextzugriff (PDF)

Molecular classification of small cell lung cancer subtypes: Characteristics, prognostic factors, and clinical translation

Chinese medical journal, 2024-01, Vol.137 (2), p.130-139

2024

Volltextzugriff (PDF)

Targeting the lactic acid metabolic pathway for antitumor therapy

Molecular therapy. Oncolytics, 2023-12, Vol.31, p.100740-100740, Article 100740

2023

Volltextzugriff (PDF)

CT-based muscle and adipose measurements predict prognosis in patients with digestive system malignancy

Scientific reports, 2024-06, Vol.14 (1), p.13036-13

2024

Volltextzugriff (PDF)

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis

Frontiers in oncology, 2020-06, Vol.10, p.904-904

2020

Volltextzugriff (PDF)

Mechanism and clinical progression of solid tumors bone marrow metastasis

Frontiers in pharmacology, 2024-05, Vol.15, p.1390361-1390361

2024

Volltextzugriff (PDF)

Resveratrol attenuates testicular apoptosis in type 1 diabetic mice: Role of Akt-mediated Nrf2 activation and p62-dependent Keap1 degradation

Redox biology, 2018-04, Vol.14, p.609-617

2018

Volltextzugriff (PDF)

Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns

Journal of cancer research and clinical oncology, 2022, Vol.148 (1), p.163-176

2022

Volltextzugriff (PDF)

Association between magnesium depletion score and the risk of metabolic dysfunction associated steatotic liver disease: a cross sectional study

Scientific reports, 2024-10, Vol.14 (1), p.24627-11, Article 24627

2024

Volltextzugriff (PDF)

Sulforaphane Protects against Cardiovascular Disease via Nrf2 Activation

Oxidative medicine and cellular longevity, 2015-01, Vol.2015 (2015), p.1-13

2015

Volltextzugriff (PDF)

Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients

Molecular and clinical oncology, 2017-09, Vol.7 (3), p.498-506

2017

Volltextzugriff (PDF)

Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)

Journal of thoracic oncology, 2021-09, Vol.16 (9), p.1533-1546

2021

Volltextzugriff (PDF)

1 – 25 von 348

Suche als RSS-Feed

Aktive Filter

KollektionNUS Single-Journal Subscriptions

SpracheChinesisch

Nur zeigenMit Volltextzugriff

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(303)

Publikationsform

Sprache

Englisch
(348)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(15)

Menü

Weitere Dienste

Einstellungen

Gamma-delta (γδ) T cells: friend or foe in cancer development?

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors

Advances and applications of RNA vaccines in tumor treatment

Regulation of fatty acid synthase on tumor and progress in the development of related therapies

Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing

The Lipid Metabolic Landscape of Cancers and New Therapeutic Perspectives

Mechanisms of Cancer Resistance to Immunotherapy

GCG inhibits SARS-CoV-2 replication by disrupting the liquid phase condensation of its nucleocapsid protein

Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy

Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

Microplastics: an often-overlooked issue in the transition from chronic inflammation to cancer

FLI-1-driven regulation of endothelial cells in human diseases

Epidermal growth factor receptor compound and concomitant mutations: advances in precision treatment strategies

Molecular classification of small cell lung cancer subtypes: Characteristics, prognostic factors, and clinical translation

Targeting the lactic acid metabolic pathway for antitumor therapy

CT-based muscle and adipose measurements predict prognosis in patients with digestive system malignancy

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis

Mechanism and clinical progression of solid tumors bone marrow metastasis

Resveratrol attenuates testicular apoptosis in type 1 diabetic mice: Role of Akt-mediated Nrf2 activation and p62-dependent Keap1 degradation

Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns

Association between magnesium depletion score and the risk of metabolic dysfunction associated steatotic liver disease: a cross sectional study

Sulforaphane Protects against Cardiovascular Disease via Nrf2 Activation

Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients

Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)

Aktive Filter

Suchergebnisse filtern